Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Veradigm ( (MDRX) ) has issued an update.
On February 20, 2025, Veradigm Inc. entered into a Cooperation Agreement with Kent Lake PR LLC, resulting in the expansion of its Board of Directors from five to six members with the appointment of Vinit K. Asar and Louis Silverman as independent directors. Additionally, the agreement stipulates the addition of two more independent directors with Kent Lake’s approval, reflecting a strategic board refreshment initiative. This move follows a request for shareholder input on board composition and aims to strengthen board governance and oversight, as the company focuses on executing its standalone strategy and financial reporting. Jonathan J. Judge resigned from the board on February 14, 2025, and Chairman Greg Garrison is set to retire following the filing of the 2022 Form 10-K.
More about Veradigm
Veradigm is a healthcare technology company that provides data-driven solutions and advanced insights for the healthcare provider, payer, and biopharma markets through its dynamic community of platforms, data, expertise, connectivity, and scale.
YTD Price Performance: -40.44%
Average Trading Volume: 506,107
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $915.6M
For an in-depth examination of MDRX stock, go to TipRanks’ Stock Analysis page.
